TrialInternational journal of clinical oncology2025

Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.

Katsuyuki Hotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.